Protocol Ledger

NCT06174220 · Phase II · RECRUITING

Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

Interventional Phase II clinical trial protocol NCT06174220 sponsored by Hamilton Health Sciences in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-21 Enrollment: 120 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06174220
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)120 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06174220
Protocol FieldVerified Registry Value
NCT IdentifierNCT06174220
Consolidated Lead SponsorHamilton Health Sciences
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment120 participants (ESTIMATED)
Registered Start Date2025-03-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06174220
Hospital Research SiteLocationSite Profile
University of CalgaryCalgary, CanadaOpen Hospital Dossier ->
London Health Sciences CentreLondon, CanadaOpen Hospital Dossier ->
Sunnybrook Health Sciences CentreToronto, CanadaOpen Hospital Dossier ->
St. Michael's HospitalToronto, CanadaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI